Novartis Gets FDA Approval IV Formulation of Cosentyx
06 Octobre 2023 - 11:11PM
Dow Jones News
By Ben Glickman
Novartis received approval from the Food and Drug Administration
for its intravenous formulation of Cosentyx, its treatment for
psoriatic arthritis and other conditions.
The pharmaceutical company said the IV delivery option would be
available in the fourth quarter.
Cosentyx, which goes by generic name secukinumab, can be used to
treat psoriatic arthritis, ankylosing spondylitis and
non-radiographic axial spondyloarthritis.
Novartis said the treatment available in IV form to block the
specific interleukin-17A, which causes inflammation associated with
certain diseases.
The company said the IV formulation would be monthly and would
take 30 minutes to administer. Novartis said the dosing option does
not require lab monitoring or pre-medication.
In the second quarter, Cosentyx brought in $1.27 billion in
sales for Novartis.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 06, 2023 16:56 ET (20:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Novartis (NYSE:NVS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
